TARS Tarsus Pharmaceuticals

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

  • William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 6:00 a.m. PT / 8:00 a.m. CT
  • Jefferies Global Healthcare Conference on Wednesday, June 4th, at 12:45 p.m. PT / 3:45 p.m. ET
  • Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th, at 10:20 a.m. PT / 1:20 p.m. ET

Live webcasts and additional information can be accessed on the events section of the Tarsus . Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex

blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea, and TP-05 as an oral tablet for the potential prevention of Lyme disease.

Media Contact:

Adrienne Kemp

Sr. Director, Corporate Communications

(949) 922-0801

Investor Contact:

David Nakasone

Head of Investor Relations

(949) 620-3223



EN
29/05/2025

Underlying

TARSTarsus Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tarsus Pharmaceuticals

 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 6:00 a.m. PT / 8:00 a.m. CTJefferies Global Healthcare Conference on Wednesday, June 4th, at 12:45 p.m. PT / 3:45 p.m. ETGoldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th, at 10:20 a.m. PT / 1:20 p.m. ET Live webcasts and additional informatio...

May 29, 2025 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, at 3:40 p.m. PT / 6:40 p.m. ETH.C. Wainwright & Co. 3rd Annual BioConnect Nasdaq Investor Conference on Tuesday, May 20th, at 12:00 p.m. PT / 3:00 p.m. ETStifel Virtual Ophthalmology Forum on Tuesday, May 27th, at 7:30 a.m. PT / 10:30 a.m. ET Live web...

May 8, 2025 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus Reports First Quarter 2025 Financial Results and Recent Busines...

Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management t...

May 1, 2025 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus to Report First Quarter 2025 Financial Results on Thursday, May...

Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. Participants may access the webcast . A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals,...

April 24, 2025 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus to Present Several Scientific Abstracts Highlighting the Global...

Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® (lotilaner ophthalmic solution) 0.25% in addressing objective measures of disease at the American Society of Catara...

April 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch